

### **REMARKS**

Claims 8-11 are pending. Claims 1-7 were previously cancelled without prejudice to or disclaimer of the underlying subject matter. Claim 8 has been amended. Claim 11 has been cancelled without prejudice to or disclaimer of the underlying subject matter. New claims 12-27 have been added. Support for the foregoing amendment and new claims can be found throughout the specification and claims as originally filed, for example on page 56, lines 5-17, page 59, lines 18-24 through page 60, line 16, page 61, lines 4-10, and page 92, lines 8-14. No new matter enters by way of the present amendment. Upon entry of the foregoing amendment claims 8-10 and 12-27 will be pending.

Applicants note that the Office indicated that the previous “restriction requirement, upon further consultation and consideration, has been withdrawn.” Examiner’s Answer dated November 12, 2004 at page 2 (emphasis in the original). In view of the withdrawal of the previous restriction requirement, Applicants note, however, that new claim 14 restates claim 8 as originally filed, *i.e.*, containing the entire Markush group of 497 nucleic acid sequences.

#### **1. Request for Continued Examination**

This application was appealed to the Board of Patent Appeals and Interferences (“Board”) on January 13, 2003. A decision by the Board of Appeals and Patent

Interferences (“Board”) was mailed on November 22, 2005. In response to that decision, Applicants file herewith a Request for Continued Examination under 37 C.F.R. § 1.114.

## **2. Claim Rejections – 35 U.S.C. § 101**

Claims 8-11 stand rejected under 35 U.S.C. § 101, because the claimed invention allegedly lacks patentable utility. Final Action at page 3. Claim 11 has been cancelled without prejudice to or disclaimer of the underlying subject matter. As such, Applicants respond as the rejection applies to claims 8-10. Applicants respectfully traverse this rejection.

The specification provides a specific, substantial, and credible utility for the claimed microarrays. For example, the specification clearly asserts that the microarrays of the present invention can be used for analyzing biological samples for the presence of maize nucleic acid sequences or for high-throughput monitoring of gene expression. *See, e.g.*, specification at page 56, lines 5-17, page 59, line 18 through page 60, line 16 and page 61, lines 4-10. The skilled artisan would have understood the utility of the claimed microarray based on such a disclosure. In addition, the claimed microarray allows for customization such that the skilled artisan can design the claimed microarrays to a given set of requirements determined by the artisan. One of ordinary skill in the art would recognize that the claimed microarrays have utility, for example, to determine whether a biological sample contains maize nucleic acid sequences or hybridizing homologues upon reading the present specification. These utilities are immediately apparent for the claimed nucleic acid molecules without further research.

Initially, claims must be considered as a whole in determining compliance with § 101. *Diamond v. Diehr*, 450 U.S. 175, 188, 209 U.S.P.Q. 1, 9 (1981). It is inappropriate to dissect claims and consider some elements while ignoring others. *Id.* The Office's rejection of the claims continues to focus on the function of the proteins encoded by one specific nucleic acid sequence recited in the Markush group on the claimed microarray. Applicants respectfully submit that they are not claiming recited nucleic acid sequences in the abstract. Applicants have disclosed nucleic acid sequences obtained from maize. The claims however are not limited to the nucleic acid sequences, but are directed as a whole to microarrays that comprise, *inter alia*, various nucleic acid sequences selected from the recited Markush group. Accordingly, the Office's arguments that the patentability of the claims is based on the utility of one nucleic acid sequence alone is improper.

Moreover, the Office acknowledges that microarrays in general have a specific and substantial utility by way of their "utility for being able to analyze a plurality of nucleic acid samples simultaneously." Examiner's Answer dated May 23, 2003 at page 8 and *see*, Board Decision mailed November 22, 2005 at page 10. The claimed microarrays similarly have the ability to analyze a large number of nucleic acid molecules in a sample simultaneously, for example, for the presence of maize nucleic acid sequences within the sample. The skilled artisan would recognize that such microarrays can be useful in identity preservation programs.

In addition, the Office acknowledges that in the Fodor and Pirrung patents, "the skilled artisan is free to select the relevant reagent (e.g., nucleic acid) of their choice to attach to the array." Board Decision at page 10. Claim 8, as well as new claims 12-27

similarly allow the skilled artisan to design or customize a particular microarray tailored to the specific requirements of the artisan. The claimed microarrays can be tailored to a given set of requirements while providing sequences selected from the recited Markush group that can act, for example, as a control to test technical performance of the array.

The “basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility...where specific benefit exists in currently available form.” *Brenner v. Manson*, 383 U.S. 519, 534-35, 148 U.S.P.Q. 689, 695 (1966). Applicants have met this part of the bargain – the present specification discloses microarrays which, in their current form, provide at least one specific benefit to the public, for example, use to analyze biological samples for the presence of maize nucleic acid sequences. *See, e.g.* Specification at page 59, lines 18-24. This benefit is specific, not vague or unknown, and it is a “real world” or substantial benefit.

The “threshold for utility is not high: An invention is ‘useful’ under section 101 if it is capable of providing some identifiable benefit.” *Juicy Whip, Inc. v. Orange Bang, Inc.*, 185 F.3d 1364, 1366, 51 U.S.P.Q.2d 1700, 1702 (Fed. Cir. 1999), *citing Brenner v. Manson*, 383 U.S. 519, 534 (1966). Furthermore, an invention need only provide one identifiable benefit to satisfy 35 U.S.C. § 101. *See Raytheon Co. v. Roper Corp.*, 724 F.2d 951, 958, 220 U.S.P.Q. 592, 598 (Fed. Cir. 1983) (“when a properly claimed invention meets at least one stated objective, utility under section 101 is clearly shown”).

The Federal Circuit has recently provided guidance as to the kind of disclosure an application could contain to establish a specific and substantial utility. *In re Fisher*, 421 F.3d 1365, 76 U.S.P.Q.2d 1225 (Fed. Cir. 2005). First, the Court indicated that the

specification disclose “that an invention is useful to the public as disclosed in its current form.” *Id.* at 1371. Second, the Court further noted that the specification “also show that that claimed invention can be used to provide a well-defined and particular benefit.” *Id.* Applicants have provided microarrays which are shown in the specification to be useful in analyzing biological samples for the presence of maize nucleic acid sequences. Such a use is sufficient to satisfy the utility standard. *Id.*

The specification discloses specific and substantial uses for the claimed microarrays, including use to analyze biological samples for the presence of maize nucleic acid sequence homologues (*see, e.g.*, specification at page 59, line 18 through page 60, line 26, and page 21, lines 11-17) and in high-throughput monitoring of gene expression in a corn plant (*see, e.g.*, specification at page 59, line 25 through page 60, line 16 and page 61, lines 4-10). Moreover, because one skilled in the art may design a microarray comprising a substrate with a variety of molecules characterized by different sequences from the recited Markush group, *see, e.g.*, claim 8, the claimed microarrays may be varied or customized to identify or screen for a particular nucleic acid molecule or molecules as designated by the designer. *See, e.g.*, Petition under 37 C.F.R. § 1.144, filed January 10, 2003, at pages 7-10. The Office argues that this utility, like many of the asserted utilities, is not specific or substantial, *see* Final Action at page 5, but does not provide any support (legal or factual) for the proposition that screening large populations of nucleic acids using the claimed microarrays is not a legally sufficient utility.

One of ordinary skill in the art would recognize that the claimed microarrays have utility, for example, to analyze biological samples for the presence of maize nucleic acid

sequences or for high-throughput monitoring of gene expression in a corn plant. These utilities are immediately apparent for the claimed microarrays without further research.

The claimed microarrays have been asserted to be useful in analyzing biological samples for the presence of maize molecules and for high-throughput monitoring of gene expression in a corn plant. These utilities provide a well-defined and particular benefit, *e.g.* to identify maize nucleic acid molecules in a sample, and these utilities are immediately useful to the public as disclosed in their current form. Accordingly, the assertion of the use of the claimed microarrays to analyze such samples satisfies the utility requirement of 35 U.S.C. § 101.

Applicants have disclosed a specific, substantial and credible utility for the claimed microarrays. Because Applicants need only establish a single utility to satisfy 35 U.S.C. § 101, and have done so in the present case, the rejection under Section 101 is incorrect. Reconsideration and withdrawal of this rejection are respectfully requested.

### **3. Claim Rejections – 35 U.S.C. § 112, first paragraph, enablement**

Claims 8-11 were rejected under 35 U.S.C. § 112, first paragraph, as not being enabled by the specification, because the claimed invention allegedly lacks utility (*i.e.*, an invention with no utility cannot be enabled). Applicants respectfully traverse this rejection, and note that this rejection has been overcome by the foregoing arguments regarding utility. Thus, the specification teaches a person of ordinary skill to make and use the claimed microarrays. Accordingly, the enablement rejection under 35 U.S.C. § 112, first paragraph, is improper. Reconsideration and withdrawal are respectfully requested.

**4. Claim Rejections – 35 U.S.C. § 112, first paragraph, written description**

Claims 8-11 stand rejected under 35 U.S.C. § 112, first paragraph because the claimed subject matter allegedly was “not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.” Final Action at page 7. Claim 11 has been cancelled without prejudice to or disclaimer of the underlying subject matter, so Applicants will respond as the rejection applies to claims 8-10. Applicants respectfully traverse this rejection.

Despite the Examiner’s admission that the SEQ ID Numbers of the Markush group (in claim 8) meet the written description provision of 35 U.S.C. § 112, first paragraph (Office Action mailed March 18, 2002, at page 7), the adequacy of the written description has been challenged by the Examiner because the microarrays of claims 8-10 are allegedly “not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.” Final Action at page 7. The bases for the Examiner’s challenge are that (1) “the claims recite the use of second nucleic acids that **comprise** the SEQ ID numbers, reading on the use of second nucleic acids that would be a full-length cDNA,” and (2) “the claims are drawn to a microarray comprising nucleic acid molecules that are complementary to the second nucleic acid molecules,” and thus would read on a full-length cDNA sequence that would hybridize to a second nucleic acid. Final Action at pages 7-8 (emphasis in original). In short, the Examiner argues that (1) one of skill in the art would allegedly conclude that Applicants were not in possession

of the nucleic acid molecules encompassed by the present invention, and (2) the specification “provides insufficient written description to support the genus encompassed by the claim.” Office Action mailed March 18, 2002, at page 8. These are not proper bases for a written description rejection of a “comprising” claim. If they were, every “comprising” claim ever written would be invalid for failing to describe every nuance of the claimed invention. Furthermore, the specification demonstrates to one skilled in the art that Applicants were in possession of the claimed microarrays comprising the claimed genera of nucleic acid molecules.

The purpose of the written description requirement is to ensure that the inventors had possession of the claimed subject matter, *i.e.*, to ensure that the inventors actually invented what is claimed. *Gentry Gallery Inc. v. Berkline Corp.*, 134 F.3d 1473, 1479, 45 U.S.P.Q.2d 1498, 1503 (Fed. Cir. 1998); *Lockwood v. American Airlines*, 107 F.3d 1565, 1572, 41 U.S.P.Q.2d 1961, 1966 (Fed. Cir. 1997); *In re Alton*, 76 F.3d 1168, 1172, 37 U.S.P.Q.2d 1578, 1581 (Fed. Cir. 1996). If a person of ordinary skill in the art would, after reading the specification, understand that the inventors had possession of the claimed invention, even if not every nuance, then the written description has been met. *In re Alton*, 76 F.3d at 1175, 37 U.S.P.Q.2d at 1584. A person of ordinary skill in the art would, after reading the present specification, understand that Applicants had possession a microarray comprising nucleic acid sequences selected from the group consisting of SEQ ID NOs: 5776, 5781, 5782, 5783, 5785, 5787, 5800, 5804, 5815, 5818, etc., and their complements, and therefore, the claimed invention.



Applicants have provided the nucleotide sequences recited by the claims, *e.g.*, SEQ ID 5776, 5781, 5782, 5783, 5785, 5787, 5800, 5804, 5815, 5818, etc., and have disclosed microarrays comprising such sequences, and have thus established possession of the claimed invention. Moreover, the present application describes more than just microarrays including the nucleotide sequences required by the claims. For example, it describes vectors comprising the claimed nucleic acid molecules, (*see, e.g.*, specification at page 67, line 14 through page 74, line 11) as well as plants transformed by the nucleic acid molecules of the present invention (*see, e.g.*, specification at page 74, line 16 to page 82, line 24). Thus, the fact that the claims at issue are intended to cover microarrays comprising nucleic acid molecules that include the recited sequences joined with additional sequences, or complements of the recited sequences does not mean that Applicants were any less in possession of the nucleic acid molecules of the claimed microarrays.<sup>1</sup> It is well-established that use of the transitional term “comprising” leaves the claims “open for the inclusion of unspecified ingredients even in major amounts.” *Ex parte Davis*, 80 U.S.P.Q. 448, 450 (B.P.A.I. 1948). *Accord PPG Indus. v. Guardian Indus.*, 156 F.3d 1351, 1354, 48 U.S.P.Q.2d 1351, 1353-54 (Fed. Cir. 1998); *Moleculon Research Corp. v. CBS*, 793 F.2d 1261, 1271, 229 U.S.P.Q. 805, 812 (Fed. Cir. 1986).

The present application describes more than just the claimed microarrays and the nucleic acid sequences of the claimed microarrays. For example, it describes how to

---

<sup>1</sup> If the Examiner is arguing that no possession is shown because the precise claim language is not used in the specification, then it goes beyond what is required by the law. It is well-settled that the description of a claimed invention need not be *in ipsius verbis*. *Gentry Gallery v. Berkline Corp.*, 134 F.3d 1473, 1479, 45 U.S.P.Q.2d 1498, 1503 (Fed.

Footnote continued on next page

make the nucleotide sequences and the libraries from which they were originally purified (specification at page 33, line 6 through page 39, line 25, and Examples 1-2). In addition, one of ordinary skill in the art has the ability to make and use the claimed microarrays based on the disclosure of the present specification, as well as envision a nucleic acid molecule that is complementary to any of the nucleic acid molecules of the claimed microarrays. Furthermore, the addition of extra nucleotides or detectable labels to the sequences present on the claimed microarrays is readily envisioned by one of ordinary skill in the art upon reading the present specification,<sup>2</sup> in particular at page 17, lines 20-24 (describing sequences with labels to facilitate detection); at page 62, line 8 through page 63, line 2 (describing site-directed mutagenesis of nucleic acid molecules); and at page 86, line 22 to page 87, line 3 (citing references describing the construction, manipulation and isolation of macromolecules). Moreover, it is well established that claims “may be broader than the specific embodiment disclosed in a specification.” *Ralston Purina Co. v. Far-mor-Co*, 772 F.2d 1570, 1575, 227 U.S.P.Q. 177, 179 (Fed. Cir. 1985) (quoting *In re Rasmussen*, 650 F.2d 1212, 1215, 211 U.S.P.Q. 323, 326 (CCPA 1981)).

The Final Action asserts that (1) “the claims recite the use of second nucleic acids that **comprise** the SEQ ID numbers, reading on the use of second nucleic acids that

---

Footnote continued from previous page  
Cir. 1998); *In re Alton*, 76 F.3d 1168, 1175, 37 U.S.P.Q.2d 1578, 1583 (Fed. Cir. 1996); *Martin v. Johnson*, 454 F.2d 746, 751, 172 U.S.P.Q. 391, 395 (C.C.P.A. 1972).

<sup>2</sup> It is established patent jurisprudence that Applicants need not teach “conventional and well-known genetic engineering techniques.” *E.g.*, *Ajinomoto Co. v. Archer-Daniels-Midland Co.*, 228 F.3d 1338, 1345, 56 U.S.P.Q.2d 1332, 1337 (Fed. Cir. 2000).

would be a full-length cDNA,” and (2) “the claims are drawn to a microarray comprising nucleic acid molecules that are complementary to the second nucleic acid molecules” Final Action at pages 7-8 (emphasis in original). The Examiner appears to assert that each nucleic acid molecule within a genus must be described by its complete structure. Office Action mailed March 18, 2002, at page 8. These assertions are totally unfounded. The Federal Circuit has elucidated a test for written description wherein a genus of nucleic acids may be described by a structural feature that distinguishes members of the claimed genus from non-members of the claimed genus. *Regents of the University of California v. Eli Lilly and Co.*, 119 F.3d 1559, 1568-69, 43 U.S.P.Q.2d 1398, 1406 (Fed. Cir. 1997) as recently amplified by *Capon v. Eshhar*, 418 F.3d 1349, 76 U.S.P.Q. 1078 (Fed. Cir. 2005). Applicants have satisfied that test for written description.

The claimed microarrays comprise combinations or collections of several genera of nucleic acid molecules. Each genus of nucleic acid molecules on the claimed microarray comprise sequences that are complementary to at least one particular enumerated nucleotide sequence, for example., SEQ ID NOs: 5776, 5781, 5782, 5783, 5785, 5787, 5800, 5804, 5815, 5818, etc. Applicants have disclosed common structural features for each genus of nucleic acid molecules, for example, SEQ ID NO: 5776. The respective common structural feature (*i.e.*, the complement or complements to a nucleotide sequence or sequences recited in the present claims) is shared by every nucleic acid molecule which may be included in a claimed microarray comprising a particular nucleic acid molecule; and the nucleic acid sequence of that nucleic acid molecule distinguishes the members of that genus of nucleic acid molecules from non-members. For example, if a microarray comprising a substrate with a surface comprising  $10^3$

nucleic acid molecules or more where at least 10% of the nucleic acid molecules are comprised of different sequences and at least about 250 nucleotide residues and complementary to a molecule comprising a sequence of SEQ ID NO: 5782, then it is a member of the claimed genus of microarrays comprising a substrate with a surface comprising  $10^3$  nucleic acid molecules or more where at least 10% of the nucleic acid molecules are comprised of different sequences and at least about 250 nucleotide residues and complementary to a molecule comprising a sequence of SEQ ID NO: 5782. If a microarray does not comprise a substrate with a surface comprising  $10^3$  nucleic acid molecules or more where at least 10% of the nucleic acid molecules are comprised of different sequences and at least about 250 nucleotide residues and complementary to a molecule comprising a sequence of SEQ ID NO: 5782, then it is not a member of that claimed genus.<sup>3</sup> The presence of other nucleotides at either end of the recited sequence will not interfere with the recognition of a claimed microarray as such – it either contains the nucleotides of SEQ ID NO: 5782 or it does not. One skilled in the art would clearly know if a microarray comprises a substrate with a surface comprising  $10^3$  nucleic acid molecules or more where at least 10% of the nucleic acid molecules are comprised of different sequences and at least about 250 nucleotide residues and complementary to a

---

<sup>3</sup> The same argument applies with equal force to every genus of the nucleic acid molecules included in the claimed microarrays. For example, if a microarray comprises a substrate with a surface comprising  $10^3$  nucleic acid molecules or more where at least 10% of the nucleic acid molecules are comprised of different sequences and at least about 250 nucleotide residues and complementary to a molecule comprising a sequence of SEQ ID NO: 5800, then it is a member of the genus of microarrays comprising a substrate with a surface comprising  $10^3$  nucleic acid molecules or more where at least 10% of the nucleic acid molecules are comprised of different sequences and at least about 250 nucleotide residues and complementary to a molecule comprising a sequence of SEQ ID NO: 5800.

molecule comprising any one or more of the recited nucleotide sequences. The fact that a nucleic acid molecule may comprise additional sequences, variations, or a full-length cDNA is beside the point. Such modifications are readily envisioned by one of ordinary skill in the art and disclosed throughout the specification.


In sum, because the specification demonstrates that Applicants had possession of the claimed microarrays, and have provided an adequate description of the claimed genera of microarrays comprising nucleic acid molecules that are complementary to a nucleic acid molecule comprising one of the recited SEQ ID NOs, the specification satisfies the written description requirement of 35 U.S.C. § 112, first paragraph, and the rejection of claims 8-10 is improper and should be withdrawn. Applicants respectfully request reconsideration and withdrawal of the rejection under 35 U.S.C. § 112, first paragraph.

### Conclusion

In view of the foregoing remarks, Applicants respectfully submit that the present application is now in condition for allowance, and notice of such is respectfully requested. The Examiner is encouraged to contact the undersigned at (202) 942-5000 should any additional information be necessary for allowance.

Respectfully submitted,

Date: January 23, 2006



Thomas E. Holsten (Reg. No. 46,098)

Holly Logue Prutz (Reg. No. 47,755)

David R. Marsh (Reg. No. 41,408)

Of Counsel:

Lawrence M. Lavin, Jr. (Reg. No. 30,768)

Thomas E. Kelley (Reg. No. 29,938)

Arnold & Porter LLP

555 Twelfth Street, N.W.

Washington, DC 20004

Tel: 202-942-5000

Fax: 202-942-5999

Correspondence Address:

Monsanto Company

Patent Department E2NA

800 N. Lindbergh Boulevard

St. Louis, Missouri 63167

Tel: 314-694-1000

Fax: 314-694-9009